Zeo ScientifiX (Zeo ScientifiX) Short-Term Debt & Capital Lease Obligation : $673 Mil (As of Jan. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Zeo ScientifiX's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $673 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Zeo ScientifiX's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $17 Mil.

Zeo ScientifiX Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Zeo ScientifiX's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX Short-Term Debt & Capital Lease Obligation Chart

Zeo ScientifiX Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.53

0.27

0.36

0.79

0.68

Zeo ScientifiX Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															0.21	0.50	0.64	0.68	673.00

Zeo ScientifiX Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Zeo ScientifiX Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Zeo ScientifiX (Zeo ScientifiX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

3321 College Avenue, Suite 246, Davie, FL, USA, 33314

Website

https://www.organicell.com

Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.

Executives

Skycrest Holdings, Llc	10 percent owner	1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider	director, officer: CEO and Director	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub	officer: Executive Vice President & CSO	23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich	officer: COO and Acting CEO	4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser	director	1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn	director	2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz	director	58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi	director	6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh	director	E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste	director
Ryan C Likes	officer: Chief Operating Officer	1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc	10 percent owner	GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey	10 percent owner	GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell	10 percent owner, officer: Chief Financial Officer	77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani	director, officer: Chief Executive Officer	4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140